Breaking Finance News

MorphoSys (ETR:MOR) target price raised to 57.00EUR, issued a report today by Commerzbank AG

Yesterday MorphoSys (ETR:MOR) traded 0.00% even at 37.04EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 42,448

MorphoSys (ETR:MOR) had its target price raised to 57.00EUR by Commerzbank AG in a report released Saturday October 01, 2016. The new target price indicates a possible upside of 0.54% based on the company's last closing price.

Previously on Friday September 30, 2016, Commerzbank AG reported on MorphoSys (ETR:MOR) raised the target price from 0.00EUR to 57.00EUR. At the time, this indicated a possible upside of 0.54%.

See Chart Below

MorphoSys (ETR:MOR)

MorphoSys has a one year low of 0.00EUR and a one year high of 0.00EUR MOR’s total market value is presently 0 EUR.

More About MorphoSys (ETR:MOR)

MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual therapeutic antibody programs, among which are in Phase III trials. MorphoSys has developed various technologies, which offer direct access to fully human antibodies for the treatment of diseases. The Company's technologies include HuCAL, which is a collection of billions of fully human antibodies and a system for their optimization, and Ylanthia, which is an antibody library in Fab format based on the concept for generating specific and fully human antibodies. It is evaluating the clinical development of approximately three cancer programs, including MOR208, MOR202 and MOR209/ES414.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.